Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Dividends

Explore dividend yields, payout ratios, and historical trends to maximize your investment strategies.

Open in Screener

RNA

Avidity Biosciences Inc

May 31 • 04:00PM ET

26.86

Dollar change -0.20
Percentage change -0.74	%

Healthcare • Biotechnology • USA • NASD

Chart Stock Detail • Compare Perf. • Revenue • Dividends • Options Options Chain • Save to Portfolio • Create Alert

Held by: VTI IWM VXF IWN IBB SCHA VTWO VHT DWAS LABU

Index	RUT	P/E	-	EPS (ttm)	-2.95	Insider Own	9.40%	Shs Outstand	95.64M	Perf Week	-2.22%
Market Cap	2.57B	Forward P/E	-	EPS next Y	-3.35	Insider Trans	-4.71%	Shs Float	86.65M	Perf Month	4.11%
Income	-228.68M	PEG	-	EPS next Q	-0.78	Inst Own	91.78%	Short Float	13.05%	Perf Quarter	33.57%
Sales	10.87M	P/S	236.33	EPS this Y	-8.78%	Inst Trans	-0.74%	Short Ratio	9.58	Perf Half Y	243.92%
Book/sh	8.69	P/B	3.09	EPS next Y	-5.75%	ROA	-29.22%	Short Interest	11.31M	Perf Year	152.92%
Cash/sh	9.58	P/C	2.80	EPS next 5Y	-	ROE	-32.91%	52W Range	4.82 - 30.84	Perf YTD	196.80%
Dividend Est.	-	P/FCF	-	EPS past 5Y	-57.60%	ROI	-27.34%	52W High	-12.91%	Beta	0.81
Dividend TTM	-	Quick Ratio	12.47	Sales past 5Y	148.90%	Gross Margin	64.89%	52W Low	456.68%	ATR (14)	1.59
Dividend Ex-Date	-	Current Ratio	12.47	EPS Y/Y TTM	12.25%	Oper. Margin	-2347.64%	RSI (14)	50.44	Volatility	6.33% 5.72%
Employees	253	Debt/Eq	0.01	Sales Y/Y TTM	12.50%	Profit Margin	-2103.78%	Recom	1.00	Target Price	45.25
Option/Short	Yes / Yes	LT Debt/Eq	0.01	EPS Q/Q	-6.13%	Payout	-	Rel Volume	0.79	Prev Close	27.06
Sales Surprise	36.18%	EPS Surprise	0.77%	Sales Q/Q	58.67%	Earnings	May 09 AMC	Avg Volume	1.18M	Price	26.86
SMA20	-2.12%	SMA50	4.39%	SMA200	96.20%	Trades		Volume	933,137	Change	-0.74%

Date	Action	Analyst	Rating Change	Price Target Change
May-03-24	Initiated	BofA Securities	Buy	$40
Mar-14-24	Initiated	Cantor Fitzgerald	Overweight	$60
May-22-23	Upgrade	Evercore ISI	In-line → Outperform	$20
Mar-31-23	Downgrade	Evercore ISI	Outperform → In-line	$20
Jul-20-22	Initiated	Chardan Capital Markets	Buy	$29
Jul-12-22	Initiated	Raymond James	Strong Buy	$29
Sep-07-21	Initiated	Evercore ISI	Outperform	$50
Jun-17-21	Initiated	Needham	Buy	$50
Apr-26-21	Resumed	Credit Suisse	Outperform	$37
Jul-07-20	Initiated	Wells Fargo	Overweight	$60
Jul-07-20	Initiated	Wells Fargo	Overweight
Jul-07-20	Initiated	SVB Leerink	Outperform
Jul-07-20	Initiated	Credit Suisse	Outperform	$34
Jul-07-20	Initiated	Credit Suisse	Outperform
Jul-07-20	Initiated	Cowen	Outperform

Show Previous Ratings

May-29-24 04:05PM	Avidity Biosciences to Present Preliminary Data from Phase 1/2 FORTITUDE Trial of AOC 1020 in People Living with Facioscapulohumeral Muscular Dystrophy at 31st Annual FSHD Society International Research Congress (PR Newswire)
08:45AM	2 Potentially High-Reward Growth Stocks to Buy Right Now (Motley Fool)
May-23-24 06:00AM	Dip Then Rip? 3 Nasdaq Stocks to Buy Before the Rebound (InvestorPlace) -7.26%
May-21-24 04:05PM	Avidity Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (PR Newswire)
May-19-24 09:03AM	Bank of America Predicts up to ~200% Surge for These 2 Strong Buy Stocks (TipRanks)
03:24AM	Loading…
May-17-24 03:24AM	Avidity Biosciences Insider Sold Shares Worth $2,121,045, According to a Recent SEC Filing (MT Newswires)
May-15-24 09:00AM	Avidity Biosciences Announces Appointment of Simona Skerjanec to Board of Directors (PR Newswire)
May-09-24 11:55PM	RNA Stock Earnings: Avidity Biosciences Misses EPS, Beats Revenue for Q1 2024 (InvestorPlace)
04:05PM	Avidity Biosciences Reports First Quarter 2024 Financial Results and Recent Highlights (PR Newswire)
May-08-24 04:05PM	Avidity Biosciences to Participate in Upcoming Investor Conference (PR Newswire)
12:27PM	Avidity Biosciences Receives FDA Breakthrough Therapy Designation for Treatment of Myotonic Dystrophy Type 1 (MT Newswires)
06:00AM	Avidity Biosciences Receives FDA Breakthrough Therapy Designation for Delpacibart Etedesiran (AOC 1001) for Treatment of Myotonic Dystrophy Type 1 (PR Newswire)
Apr-22-24 04:05PM	Avidity Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (PR Newswire) +6.29%
Apr-04-24 01:30AM	Insider Sell: Avidity Biosciences Inc (RNA) President and CEO Sarah Boyce Sells 28,000 Shares (GuruFocus.com) -11.07%
Mar-27-24 09:00AM	Avidity Biosciences to Participate in Upcoming Investor Conferences (PR Newswire)
04:05PM	Loading…
Mar-21-24 04:05PM	Avidity Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (PR Newswire)
Mar-15-24 07:01PM	Insider Sell: CFO Michael Maclean Sells 40,000 Shares of Avidity Biosciences Inc (RNA) (GuruFocus.com)
Mar-04-24 04:02PM	Top 2% Biotech Avidity Tumbles Despite 'Positive' Results In Treating Muscular Dystrophy (Investor's Business Daily) -6.22%
07:00AM	Avidity Biosciences Announces Positive AOC 1001 Long-term Data Showing Reversal of Disease Progression in People Living with Myotonic Dystrophy Type 1 Across Multiple Endpoints; Same Key Endpoints Agreed for Phase 3 HARBOR Trial (PR Newswire)
Feb-29-24 12:00PM	Avidity Biosciences Honors Rare Disease Day (PR Newswire) +19.92%
07:00AM	Avidity Biosciences Announces Oversubscribed $400 Million Private Placement (PR Newswire)
Feb-28-24 05:20PM	Avidity Biosciences, Inc. (RNA) Reports Q4 Loss, Misses Revenue Estimates (Zacks)
04:40PM	Avidity Biosciences Inc (RNA) Reports Year-End Financials and Clinical Progress (GuruFocus.com)
04:05PM	Avidity Biosciences Reports Fourth Quarter and Year-End 2023 Financial Results and Recent Highlights (PR Newswire)
Feb-27-24 09:00AM	Avidity Biosciences to Participate in Upcoming Investor Conferences (PR Newswire) +5.51%
Feb-26-24 06:55AM	3 Highly Rated Biotech Stocks to Buy for 300% Gains (InvestorPlace)
Feb-21-24 04:05PM	Avidity Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (PR Newswire)
Feb-20-24 09:00AM	Avidity Biosciences Receives FDA Rare Pediatric Disease Designation for AOC 1044 for Treatment of Duchenne Muscular Dystrophy in People with Mutations Amenable to Exon 44 Skipping (PR Newswire)
Feb-15-24 05:00PM	Avidity Biosciences to Present New AOC 1001 Long-term Efficacy and Safety Data from MARINA-OLE Trial in People Living with Myotonic Dystrophy Type 1 (DM1) at 2024 Muscular Dystrophy Association (MDA) Clinical & Scientific Conference (PR Newswire)
Jan-29-24 08:54AM	Strength Seen in Avidity Biosciences, Inc. (RNA): Can Its 15.0% Jump Turn into More Strength? (Zacks)
04:05PM	Loading…
Jan-22-24 04:05PM	Avidity Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (PR Newswire)
Jan-05-24 08:30AM	Avidity Biosciences Announces 2024 Corporate Priorities and Catalysts for Next Stage of Growth (PR Newswire)
Dec-21-23 04:05PM	Avidity Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (PR Newswire) +8.10%
Dec-13-23 08:30AM	Avidity Biosciences Reports Positive Data Demonstrating AOC 1044 Delivers Unprecedented Concentrations of PMO in Muscle Following a Single Dose in Healthy Volunteers from Phase 1/2 EXPLORE44 Trial for Duchenne Muscular Dystrophy (PR Newswire) +10.28%
Nov-29-23 09:03AM	Avidity (RNA) Expands Collaboration With BMY, Shares Rise (Zacks) +10.31%
Nov-28-23 10:09AM	Why Is Avidity Biosciences (RNA) Stock Up 15% Today? (InvestorPlace) +14.94%
10:02AM	Avidity Stock Soars on Collaboration Deal With Bristol Myers (Barrons.com)
07:01AM	Bristol Myers pours $100M into RNA drugs for cardiovascular diseases (BioPharma Dive)
06:30AM	Avidity Biosciences Announces Expansion of Cardiovascular Collaboration with Bristol Myers Squibb for up to Five Targets Utilizing Avidity's Proprietary AOC Platform Technology (PR Newswire)
Nov-21-23 04:05PM	Avidity Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (PR Newswire)
09:00AM	Avidity Biosciences to Participate in Upcoming Investor Conference (PR Newswire)
Nov-08-23 06:12PM	Avidity Biosciences Inc (RNA) Reports Third Quarter 2023 Financial Results and Recent Highlights (GuruFocus.com) -7.03%
04:05PM	Avidity Biosciences Reports Third Quarter 2023 Financial Results and Recent Highlights (PR Newswire)
Oct-23-23 04:05PM	Avidity Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (PR Newswire) -6.49%
Oct-07-23 07:30AM	Avidity Biosciences Announces New Positive AOC 1001 Data Demonstrating Improvement in Multiple Additional Functional Endpoints and Favorable Long-term Safety and Tolerability in People with Myotonic Dystrophy Type 1 (PR Newswire)
Sep-26-23 09:00AM	Avidity Biosciences Announces Upcoming Presentations at 28th Annual Congress of the World Muscle Society (PR Newswire)
Sep-25-23 09:00AM	Avidity Biosciences to Participate in Upcoming Investor Conferences (PR Newswire)
Sep-21-23 04:05PM	Avidity Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (PR Newswire)
Sep-11-23 07:28PM	Down More Than 50%: Analysts Say Buy These 2 Beaten-Down Stocks Before They Rebound (TipRanks)
Sep-07-23 09:00AM	Avidity Biosciences Joins with Patient Communities to Raise Awareness During National Muscular Dystrophy Awareness Month as it Advances Three Muscular Dystrophy Clinical Programs (PR Newswire)
Aug-31-23 09:00AM	Avidity Biosciences Announces Upcoming Presentations at 2023 Myotonic Dystrophy Foundation Annual Conference (PR Newswire) -5.14%
Aug-30-23 09:00AM	Avidity Biosciences to Participate in Upcoming Investor Conferences (PR Newswire)
Aug-21-23 04:05PM	Avidity Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (PR Newswire)
Aug-15-23 09:00AM	Avidity Biosciences Receives FDA Orphan Drug Designation for AOC 1044 for Treatment of Duchenne Muscular Dystrophy in People with Mutations Amenable to Exon 44 Skipping (PR Newswire)
Aug-08-23 07:15PM	Avidity Biosciences, Inc. (RNA) Reports Q2 Loss, Tops Revenue Estimates (Zacks)
04:05PM	Avidity Biosciences Reports Second Quarter 2023 Financial Results and Recent Highlights (PR Newswire)
Jul-21-23 04:05PM	Avidity Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (PR Newswire)
Jul-12-23 07:24AM	Avidity Biosciences (NASDAQ:RNA) shareholders have endured a 59% loss from investing in the stock three years ago (Simply Wall St.)
Jun-21-23 04:05PM	Avidity Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (PR Newswire)
Jun-20-23 09:00AM	Avidity Biosciences Joins with Patients, Caregivers and Healthcare Providers Globally to Support World Facioscapulohumeral Muscular Dystrophy (FSHD) Day (PR Newswire)
Jun-08-23 09:00AM	Avidity Biosciences Announces Upcoming Presentations at the 30th Annual FSHD Society International Research Congress (PR Newswire)
May-22-23 04:05PM	Avidity Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (PR Newswire) +11.65%
May-17-23 12:38PM	FDA Eases Partial Hold On Avidity Biosciences' Investigational Drug Study In Type Of Dystrophy (Benzinga)
07:00AM	Avidity Biosciences Announces FDA Eases Partial Clinical Hold on AOC 1001 Providing a Clear Path Forward to Finalize Pivotal Dose and Phase 3 Design in Adults with Myotonic Dystrophy Type 1 (PR Newswire)
May-09-23 06:15PM	Avidity Biosciences, Inc. (RNA) Reports Q1 Loss, Tops Revenue Estimates (Zacks)
04:05PM	Avidity Biosciences Reports First Quarter 2023 Financial Results and Recent Highlights (PR Newswire)
May-04-23 09:00PM	Ikena Oncology, Inc. (IKNA) Stock Jumps 7.9%: Will It Continue to Soar? (Zacks)
Apr-28-23 10:08AM	Avidity Biosciences Touts Encouraging Data From Myotonic Dystrophy Type 1 Study (Benzinga) -14.78%
Apr-27-23 03:40PM	Avidity Biosciences Announces Positive Topline Data from AOC 1001 Phase 1/2 MARINA Trial Demonstrating Functional Improvement, Disease Modification and Favorable Safety and Tolerability Profile in People Living with Myotonic Dystrophy Type 1 (PR Newswire) -16.09%
Apr-24-23 09:00AM	Avidity Biosciences Granted FDA Fast Track Designation for AOC 1044 for Treatment of Duchenne Muscular Dystrophy Mutations Amenable to Exon 44 Skipping (PR Newswire)
Apr-21-23 04:05PM	Avidity Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (PR Newswire)
Apr-17-23 09:00AM	Avidity Biosciences Announces Upcoming Presentations at the 75th American Academy of Neurology Annual Meeting (PR Newswire) +8.08%
Apr-13-23 09:00AM	Avidity Biosciences to Host Investor and Analyst Event Focused on AOC 1001 Topline Data from Phase 1/2 MARINA Trial on April 27, 2023 (PR Newswire) +9.08%
Apr-11-23 11:23AM	After Falling 18% in 1 Day, Is This Growth Stock Done For? (Motley Fool)
Apr-05-23 10:14AM	Biotech Stock Roundup: BLUE Announces Q4 Results, ONCT, ASND & RNA Fall on Updates (Zacks)
Mar-31-23 11:44AM	Avidity (RNA) Down on Update From Neuromuscular Disease Study (Zacks) -8.63%
Mar-30-23 04:16PM	Avidity Bio Crashes 17% After 'Rarer Than Rare' Event Sidelines Key Study (Investor's Business Daily) -16.83%
03:25PM	Why Avidity Biosciences Shares Are Sliding Today (Benzinga)
07:00AM	Avidity Biosciences Provides Regulatory Update on AOC 1001 for Myotonic Dystrophy Type 1 and Plans to Present Top-line Data from Phase 1/2 MARINA Trial at AAN Annual Meeting (PR Newswire)
Mar-25-23 10:17AM	Avidity Biosciences (NASDAQ:RNA) Is In A Good Position To Deliver On Growth Plans (Simply Wall St.)
Mar-21-23 04:05PM	Avidity Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (PR Newswire)
Mar-13-23 09:00AM	Avidity Biosciences Announces Upcoming Presentations at 2023 MDA Clinical & Scientific Conference (PR Newswire)
Mar-01-23 04:05PM	Avidity Biosciences to Participate in Upcoming Investor Conference (PR Newswire)
Feb-28-23 07:45PM	Avidity Biosciences, Inc. (RNA) Reports Q4 Loss, Tops Revenue Estimates (Zacks)
04:05PM	Avidity Biosciences Reports Fourth Quarter and Year-End 2022 Financial Results and Recent Highlights (PR Newswire)
09:00AM	Avidity Biosciences Honors Rare Disease Day® (PR Newswire)
Feb-27-23 04:40PM	Analyst Says This Small Cap Biotech Firm Has 'Very Valuable Therapeutic,' Upgrades Stock (Benzinga)
08:00AM	Avidity Advances RNA Programs and Expands into New Therapeutic Areas Utilizing its AOC Platform (PR Newswire)
Feb-23-23 08:00AM	Avidity Biosciences Announces Arthur A. Levin to Join Board of Directors and Transition to Distinguished Scientist and Strategic Leader (PR Newswire)
Feb-21-23 08:29PM	Avidity Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (PR Newswire) -9.59%
Feb-14-23 09:00AM	Avidity Biosciences Receives FDA Orphan Drug Designation for AOC 1020 for the Treatment of Facioscapulohumeral Muscular Dystrophy (PR Newswire)
Feb-07-23 09:00AM	Avidity Biosciences to Participate in Upcoming Investor Conference (PR Newswire)
Feb-02-23 05:17AM	The one-year returns have been notable for Avidity Biosciences (NASDAQ:RNA) shareholders despite underlying losses increasing (Simply Wall St.)
Jan-20-23 05:12PM	Avidity Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (PR Newswire)
Jan-18-23 09:00AM	Avidity Biosciences Granted FDA Fast Track Designation for AOC 1020 for the Treatment of Facioscapulohumeral Muscular Dystrophy (PR Newswire)
Dec-23-22 06:48AM	Following a 16% decline over last year, recent gains may please Avidity Biosciences, Inc. (NASDAQ:RNA) institutional owners (Simply Wall St.)
Dec-15-22 07:37PM	Avidity Biosciences, Inc. Announces Pricing of Upsized Public Offering of Common Stock (PR Newswire) +6.45%
07:00AM	Avidity Biosciences, Inc. Announces Proposed Public Offering of Common Stock (PR Newswire)
Dec-14-22 07:22PM	This Genetic Medicine Stock Soars Over 50% on Industry First (TheStreet.com) +55.28%
04:10PM	How A First-Ever In Gene Silencing Catapulted Avidity Biosciences Into The Stratosphere (Investor's Business Daily)

Avidity Biosciences, Inc. engages in the development of a new class of oligonucleotide-based therapies called Antibody Oligonucleotide Conjugates (AOC). It utilizes its AOC platform to design, engineer, and develop therapeutics that combine the tissue selectivity of monoclonal antibodies and the precision of oligonucleotide-based therapies in order to access previously undruggable tissue and cell types and more effectively target underlying genetic drivers of diseases. The company was founded by Troy E. Wilson, Kent Hawryluk, Mark E. Davis, and Francis Patrick McCormick on November 13, 2012 and is headquartered in San Diego, CA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
LEVIN ARTHUR A	Director	May 20 '24	Option Exercise	1.24	5,000	6,200	19,830	May 21 05:05 PM
LEVIN ARTHUR A	Director	May 20 '24	Sale	29.90	5,000	149,481	14,830	May 21 05:05 PM
MacLean Michael F	Chief Financial Officer	May 14 '24	Option Exercise	8.82	75,000	661,500	119,093	May 16 06:25 PM
MacLean Michael F	Chief Financial Officer	May 14 '24	Sale	28.28	75,000	2,121,045	44,093	May 16 06:25 PM
Boyce Sarah	President and CEO	May 07 '24	Option Exercise	1.24	28,000	34,720	140,117	May 07 09:52 PM
Boyce Sarah	President and CEO	May 07 '24	Sale	25.54	28,000	715,050	112,117	May 07 09:52 PM
LEVIN ARTHUR A	Director	Apr 19 '24	Option Exercise	1.24	5,000	6,200	19,830	Apr 22 05:28 PM
LEVIN ARTHUR A	Director	Apr 19 '24	Sale	22.82	5,000	114,123	14,830	Apr 22 05:28 PM
LEVIN ARTHUR A	Director	Apr 03 '24	Sale	27.11	20,000	542,214	253,872	Apr 03 08:26 PM
Boyce Sarah	President and CEO	Apr 02 '24	Option Exercise	1.24	28,000	34,720	140,117	Apr 03 06:16 PM
Boyce Sarah	President and CEO	Apr 02 '24	Sale	26.25	28,000	734,919	112,117	Apr 03 06:16 PM
LEVIN ARTHUR A	Director	Mar 19 '24	Option Exercise	1.24	5,000	6,200	19,830	Mar 21 04:10 PM
LEVIN ARTHUR A	Director	Mar 19 '24	Sale	23.97	5,000	119,848	14,830	Mar 21 04:10 PM
MacLean Michael F	Chief Financial Officer	Mar 13 '24	Option Exercise	8.82	40,000	352,800	84,093	Mar 15 04:12 PM
MacLean Michael F	Chief Financial Officer	Mar 13 '24	Sale	24.52	40,000	980,760	44,093	Mar 15 04:12 PM
Boyce Sarah	President and CEO	Mar 12 '24	Option Exercise	1.24	28,000	34,720	140,117	Mar 12 05:29 PM
LEVIN ARTHUR A	Director	Mar 12 '24	Option Exercise	1.24	25,000	31,000	42,471	Mar 12 08:41 PM
Boyce Sarah	President and CEO	Mar 12 '24	Sale	22.63	28,000	633,682	112,117	Mar 12 05:29 PM
LEVIN ARTHUR A	Director	Mar 12 '24	Sale	22.03	27,641	609,017	14,830	Mar 12 08:41 PM
Boyce Sarah	President and CEO	Mar 08 '24	Option Exercise	1.24	84,000	104,160	196,117	Mar 12 05:29 PM
Boyce Sarah	President and CEO	Mar 08 '24	Sale	21.39	84,000	1,796,710	112,117	Mar 12 05:29 PM
Boyce Sarah	President and CEO	Mar 01 '24	Option Exercise	1.24	84,000	104,160	196,117	Mar 05 04:53 PM
Boyce Sarah	President and CEO	Mar 01 '24	Sale	20.13	84,000	1,691,306	112,117	Mar 05 04:53 PM
Boyce Sarah	President and CEO	Jan 22 '24	Sale	10.13	5,092	51,582	44,008	Jan 23 03:13 PM
Flanagan W. Michael	CSTO	Jan 22 '24	Sale	10.13	4,129	41,827	35,871	Jan 23 03:12 PM
McCarthy Teresa	Chief Human Resources Officer	Jan 22 '24	Sale	10.13	2,065	20,918	17,035	Jan 23 03:11 PM
LEVIN ARTHUR A	Director	Jan 22 '24	Sale	10.13	1,859	18,832	17,471	Jan 23 03:14 PM
MacLean Michael F	Chief Financial Officer	Jan 22 '24	Sale	10.13	1,616	16,370	16,884	Jan 23 03:11 PM

Open in Screener

OABI

OmniAb Inc

May 31 • 04:00PM ET

4.34

Dollar change -0.14
Percentage change -3.12	%

Healthcare • Biotechnology • USA • NASD

Chart Stock Detail • Compare Perf. • Revenue • Dividends • Options Options Chain • Save to Portfolio • Create Alert

Held by: VTI IWM VXF IWN SCHA VTWO VHT DFAS DFAC IWC

Index	RUT	P/E	-	EPS (ttm)	-0.63	Insider Own	19.51%	Shs Outstand	116.86M	Perf Week	1.17%
Market Cap	508.34M	Forward P/E	-	EPS next Y	-0.41	Insider Trans	2.88%	Shs Float	94.28M	Perf Month	-4.82%
Income	-63.48M	PEG	-	EPS next Q	-0.17	Inst Own	59.31%	Short Float	5.91%	Perf Quarter	-26.57%
Sales	21.05M	P/S	24.15	EPS this Y	-24.02%	Inst Trans	0.72%	Short Ratio	10.22	Perf Half Y	-3.34%
Book/sh	2.57	P/B	1.69	EPS next Y	35.18%	ROA	-16.58%	Short Interest	5.58M	Perf Year	0.46%
Cash/sh	0.59	P/C	7.37	EPS next 5Y	-	ROE	-19.77%	52W Range	4.17 - 6.72	Perf YTD	-29.66%
Dividend Est.	-	P/FCF	-	EPS past 5Y	-	ROI	-19.66%	52W High	-35.37%	Beta	-0.04
Dividend TTM	-	Quick Ratio	4.38	Sales past 5Y	13.92%	Gross Margin	6.93%	52W Low	4.08%	ATR (14)	0.19
Dividend Ex-Date	-	Current Ratio	4.38	EPS Y/Y TTM	-384.71%	Oper. Margin	-395.91%	RSI (14)	43.17	Volatility	4.54% 3.86%
Employees	106	Debt/Eq	0.08	Sales Y/Y TTM	-59.73%	Profit Margin	-301.63%	Recom	1.00	Target Price	9.88
Option/Short	Yes / Yes	LT Debt/Eq	0.07	EPS Q/Q	-206.02%	Payout	-	Rel Volume	0.99	Prev Close	4.48
Sales Surprise	-35.24%	EPS Surprise	-17.79%	Sales Q/Q	-77.53%	Earnings	May 09 AMC	Avg Volume	545.75K	Price	4.34
SMA20	-3.42%	SMA50	-9.56%	SMA200	-16.84%	Trades		Volume	541,150	Change	-3.12%

Date	Action	Analyst	Rating Change	Price Target Change
Nov-29-23	Initiated	RBC Capital Mkts	Outperform	$6
Apr-21-23	Initiated	The Benchmark Company	Buy	$8
Apr-13-23	Initiated	Craig Hallum	Buy	$10
Feb-22-23	Initiated	Cowen	Outperform	$10
Feb-13-23	Initiated	H.C. Wainwright	Buy	$11
Dec-20-22	Initiated	Truist	Buy	$10
Dec-16-22	Initiated	Credit Suisse	Outperform	$13
Nov-29-22	Initiated	SVB Leerink	Outperform	$6
Nov-28-22	Initiated	Stifel	Buy	$12

May-20-24 08:05AM	OmniAb to Participate in the Jefferies Global Healthcare Conference (Business Wire)
May-15-24 04:05PM	OmniAb Presents High-Throughput Single B-cell Screening xPloration Data at the 20th Annual PEGS Boston Summit (Business Wire)
May-12-24 03:24PM	5 Penny Stocks with Insider Buying in 2024 (Insider Monkey)
May-09-24 08:56PM	OABI Stock Earnings: OmniAb Misses EPS, Misses Revenue for Q1 2024 (InvestorPlace)
04:05PM	OmniAb Reports First Quarter 2024 Financial Results and Business Highlights (Business Wire)
08:00AM	Loading…
May-01-24 08:00AM	OmniAb to Participate in Five Investor Conferences in May (Business Wire)
Apr-22-24 08:00AM	OmniAb to Report First Quarter 2024 Financial Results on May 9 (Business Wire)
Mar-21-24 11:31AM	OmniAb, Inc. (NASDAQ:OABI) Q4 2023 Earnings Call Transcript (Insider Monkey) -5.17%
Mar-20-24 08:54PM	OABI Stock Earnings: OmniAb Beats EPS, Misses Revenue for Q4 2023 (InvestorPlace)
04:05PM	OmniAb Reports Fourth Quarter and Full Year 2023 Financial Results and Business Highlights (Business Wire)
Feb-28-24 08:27AM	OmniAb, Inc. (OABI) Soars 10.5%: Is Further Upside Left in the Stock? (Zacks)
Feb-26-24 08:00AM	OmniAb to Report Fourth Quarter 2023 Financial Results on March 20 (Business Wire)
Feb-20-24 08:00AM	OmniAb to Participate in Two Investor Conferences in March (Business Wire)
Dec-14-23 04:30PM	OmniAb Presents New Scientific Data on its OmnidAb Platform at the 2023 Antibody Engineering & Therapeutics Conference (Business Wire)
Nov-20-23 12:39PM	OmniAb, Inc. (NASDAQ:OABI) Q3 2023 Earnings Call Transcript (Insider Monkey)
05:03AM	Loading…
Nov-14-23 05:03AM	Insider Buying: OmniAb Inc CEO Matthew Foehr Acquires 95,000 Shares (GuruFocus.com) +6.32%
Nov-09-23 05:55PM	OmniAb Highlights OmnidAb Launch and its Expanding Drug Discovery Platform at Todays Research & Technology Virtual Event (Business Wire)
09:24AM	OmniAb Inc (OABI) Reports Decline in Q3 Revenue and Widening Net Loss (GuruFocus.com)
08:00AM	OmniAb Reports Third Quarter 2023 Financial Results and Business Highlights (Business Wire)
Nov-02-23 08:00AM	OmniAb to Participate in Two Investor Conferences in November (Business Wire)
Nov-01-23 09:00AM	OmniAb Appoints Steve Love to its Board of Directors (Business Wire)
Oct-31-23 04:28PM	OmniAb Announces Agenda for its Research & Technology Virtual Event (Business Wire)
Oct-26-23 02:32PM	7 of the Best Cheap Stocks to Buy Under $5 in October 2023 (InvestorPlace)
Oct-12-23 08:00AM	OmniAb to Hold Research & Technology Virtual Event on November 9 (Business Wire)
Sep-05-23 08:00AM	OmniAb to Participate in Two Investor Conferences in September (Business Wire)
Aug-15-23 05:20AM	OmniAb, Inc. (NASDAQ:OABI) Q2 2023 Earnings Call Transcript (Insider Monkey)
Aug-13-23 08:06AM	OmniAb, Inc. (NASDAQ:OABI) Analysts Are Cutting Their Estimates: Here's What You Need To Know (Simply Wall St.)
Aug-10-23 04:05PM	OmniAb Reports Second Quarter 2023 Financial Results and Business Highlights (Business Wire)
Aug-07-23 04:05PM	OmniAb Announces the Passing of Director Sunil Patel (Business Wire)
Jul-31-23 08:00AM	OmniAb to Report Second Quarter 2023 Financial Results on August 10 (Business Wire)
07:35AM	Loading…
Jul-17-23 07:35AM	With 60% institutional ownership, OmniAb, Inc. (NASDAQ:OABI) is a favorite amongst the big guns (Simply Wall St.)
Jun-13-23 06:00AM	7 Stocks to Buy for 200% Returns This Year (InvestorPlace) +6.32%
May-18-23 05:09PM	7 Stocks to Buy for Their Massive Upside Potential (InvestorPlace)
May-17-23 04:05PM	OmniAb Launches OmniDeep at the PEGS Boston Conference and Expo (Business Wire)
May-16-23 06:06AM	President of OmniAb Matthew Foehr Buys 22% More Shares \ (Simply Wall St.) +9.12%
May-14-23 08:03AM	OmniAb, Inc. (NASDAQ:OABI) Analysts Just Cut Their EPS Forecasts Substantially (Simply Wall St.)
May-11-23 10:55PM	Q1 2023 OmniAb Inc Earnings Call (Thomson Reuters StreetEvents)
07:00AM	OmniAb Reports First Quarter 2023 Financial Results and Business Highlights (Business Wire)
May-05-23 07:14AM	OmniAb, Inc.'s (NASDAQ:OABI) Share Price Matching Investor Opinion (Simply Wall St.)
May-04-23 06:26AM	10 Best Small-Cap Growth Stocks to Buy Now (Insider Monkey)
May-01-23 08:00AM	OmniAb to Report First Quarter 2023 Financial Results on May 11 (Business Wire)
Apr-26-23 08:01PM	7 Biotech Stocks With Huge Return Potential for Long-Term Investors (InvestorPlace)
Apr-25-23 08:00AM	OmniAb to Participate in Upcoming Investor Conferences in May (Business Wire)
Apr-19-23 08:30AM	Here's How Much a $1000 Investment in Ligand Pharmaceuticals Made 10 Years Ago Would Be Worth Today (Zacks)
Apr-07-23 10:24PM	OmniAb, Inc. (NASDAQ:OABI) Q4 2022 Earnings Call Transcript (Insider Monkey)
Apr-05-23 06:09AM	OmniAb Full Year 2022 Earnings: Beats Expectations (Simply Wall St.)
Apr-02-23 08:51AM	Insiders of OmniAb, Inc. (NASDAQ:OABI) are up 11% on their US$2.3m purchase after OmniAb, Inc. (NASDAQ:OABI) rose 14% last week (Simply Wall St.)
Mar-31-23 08:40AM	Do Options Traders Know Something About OmniAb (OABI) Stock We Don't? (Zacks)
Mar-30-23 04:05PM	OmniAb Reports Fourth Quarter and Full Year 2022 Financial Results and Business Highlights (Business Wire)
Mar-15-23 11:44AM	7 Biotech Stocks That Could Be the Next Big Thing (InvestorPlace)
Mar-09-23 08:00AM	OmniAb to Report Fourth Quarter 2022 Financial Results on March 30 (Business Wire) -5.03%
Mar-08-23 09:53AM	These 2 Strong Buy Penny Stocks Are Poised for a Massive Rally, Say Analysts (TipRanks)
Feb-23-23 07:49AM	Ligand's (LGND) Q4 Sales & Earnings Top, View Raised, Stock Up (Zacks)
Feb-07-23 08:00AM	OmniAb to Participate in Three Upcoming Investor Conferences (Business Wire)
Feb-01-23 06:56AM	With 44% stake, OmniAb, Inc. (NASDAQ:OABI) seems to have captured institutional investors' interest (Simply Wall St.)
Dec-16-22 12:39PM	Some 'Transgenic Animal Platforms Are More Than Equal,' Analyst Initiating Coverage On OmniAb Says (Benzinga)
Dec-01-22 08:47AM	Hillstream BioPharma Announces Development of Proprietary Targeted Biologics, Knob Quatrabodies (HSB-1940) against PD-1, by combining Quatramers with OmniAbs Picobodies, via a Collaboration Agreement, against Novel, Unreachable and Undruggable Epitopes in High Value Validated Targets (GlobeNewswire) -5.37%
Nov-15-22 07:00AM	OmniAb Reports Third Quarter 2022 Financial Results and Business Highlights (Business Wire) -10.00%
Nov-03-22 08:00AM	OmniAb to Participate in Two Upcoming Investor Conferences (Business Wire)
Nov-02-22 07:00AM	OmniAb, Inc. to Ring Nasdaq Stock Market Opening Bell (Business Wire) -60.65%
Nov-01-22 04:01PM	OmniAb Announces Completion of Spin-Off and Business Combination (Business Wire) -9.26%
04:01PM	Ligand Announces Completion of OmniAb Spin-Off (Business Wire)

OmniAb, Inc. operates as a drug discovery company. It focuses on developing human monoclonal and bispecific therapeutic antibodies. Its platform includes the biological intelligence of its transgenic animals, including OmniRat, OmniChicken and OmniMouse. The company was founded on December 14, 2015 and is headquartered in Emeryville, CA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
FOEHR MATTHEW W	President and CEO	May 24 '24	Buy	4.42	240,000	1,059,840	3,536,665	May 28 05:55 PM
GUSTAFSON KURT A	Executive VP, Finance and CFO	Apr 08 '24	Sale	5.27	6,954	36,648	176,697	Apr 09 06:38 PM
Berkman Charles S	Chief Legal Officer	Apr 08 '24	Sale	5.27	6,954	36,648	292,617	Apr 09 06:37 PM
GUSTAFSON KURT A	Executive VP, Finance & CFO	Apr 01 '24	Sale	5.46	11,849	64,696	170,110	Apr 02 06:30 PM
FOEHR MATTHEW W	President and CEO	Mar 27 '24	Option Exercise	3.72	243,613	907,023	3,152,416	Mar 29 04:52 PM
FOEHR MATTHEW W	President and CEO	Mar 22 '24	Buy	5.19	225,000	1,167,750	2,908,803	Mar 25 07:07 AM
FOEHR MATTHEW W	Chief Executive Officer	Dec 12 '23	Buy	5.05	200,000	1,010,000	2,645,442	Dec 13 03:25 PM
FOEHR MATTHEW W	President and CEO	Nov 10 '23	Buy	4.27	95,000	405,517	2,427,919	Nov 13 08:00 AM
FOEHR MATTHEW W	President and CEO	Aug 14 '23	Buy	5.48	45,000	246,600	2,332,919	Aug 15 04:56 PM
FOEHR MATTHEW W	Chief Executive Officer	Jun 09 '23	Buy	4.52	115,000	519,800	2,574,009	Jun 12 04:47 PM

affiliate • advertise • toggle light mode • contact • privacy • help
do not sell my data • privacy settings

RNA

Avidity Biosciences Inc

OABI

OmniAb Inc

Upgrade your FINVIZ experience